Business
OptimizeRx Authorizes $20 Million Share Repurchase Program
ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions

About this update from Optimizerx Corporation
[{"type":"text","content":"ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $20 million of its outstanding common stock. Will Febbo, OptimizeRx CEO commented, \"The authorization of the buyback reflects our focus on disciplined capital allocation strategies to drive shareholder returns. The share buyback program highlights the conviction our Board has in our Company’s outlook, financial strength, industry positioning, and dedication to drive value for our various stakeholders.” “We intend to opportunistically repurchase shares of our common stock, while maintaining a strong working capital position to fuel our future growth. We will maintain our focus on both organic growth and M&A activity and believe we have ample cash to do both.\" concluded Mr. Febbo. About OptimizeRxOptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performa...